Featured News

Thank you to ImmunogenX for sponsoring our upcoming Patient Education and Advocacy Summit. ImmunogenX is a clinical stage biopharmaceutical company focused on developing therapeutic and diagnostic solutions for celiac disease. Registration closes soon so be sure to register today!

Thank you to Glutenostics for sponsoring our upcoming Patient Education and Advocacy Summit. Through the licensing, development, and commercialization of novel technologies, Glutenostics is bringing new tools to market that address the unmet needs of millions of Americans avoiding gluten for health concerns. Register now to be a part of this monumental event!

Thank you to Takeda for sponsoring our upcoming Patient Education and Advocacy Summit. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides toward closing the gap on unmet needs for patients who have celiac disease. Register now to be a part of this momentous event!

Thank you to Kanyos Bio, Inc., for sponsoring our upcoming Patient Education and Advocacy Summit. They are working to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. Register now!

Thank you to 9 Meters for sponsoring our upcoming Patient Education and Advocacy Summit. 9 Meters is a gastroenterology-focused therapeutics company targeting GI diseases with unmet needs. Register now!

Thank you to Schär for sponsoring our upcoming Patient Education and Advocacy Summit. For over 35 years, Schär has been dedicated to the celiac and gluten-sensitive communities by providing a safe, flavorful, and quality line of gluten-free products. Learn more about Schär’s collection of gluten-free goods.

Initial findings of the first mass screening study for U.S. children show a high prevalence of celiac disease autoimmunity (CDA) among those without symptoms and no family history of the condition.

I want to share with you highlights of our advocacy plans for 2021. Our work in Washington, DC, with Congress, with the NIH, FDA, and other agencies, is critical in the pursuit of treatments and a cure for celiac disease.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.